Are you ready? The new era of targeted local chemotherapy for retinoblastoma is coming

Authors: Chen Danian,  Gao Jingge
DOI: 10.3760/cma.j.issn.2095-0160.2015.11.001
Published 2015-11-10
Cite as Chin J Exp Ophthalmol, 2015,33(11): 961-964.

Abstract                              [Download PDF] [Read Full Text]

Retinoblastoma (RB) therapy has evolved over decades.In the 1970s, enucleation was important for improving life prognosis.In the 1980s, external beam radiotherapy (EBRT) was popular.In the 1990s, systemic intravenous chemotherapy (IVC) was introduced and currently remains prevalent worldwide for intraocular RB control as well as prevention of systemic metastasis.However, RB seeds in vitreous and subretinal space are still the major obstacles for successful treatments.Advanced ophthalmic imaging technology promotes thorough and detailed description and observation of RB seeds.In the 2000s, interests in periocular chemotherapy (POC), intra-arterial chemotherapy (IAC) and intravitreous chemotherapy (IVitC) have been explored to overcome the low drug concentration around the seeds and to reduce the systemic side effects.This leads us into a new era of target local chemotherapy of RB.How to make the treatment decision based on biological behavior of RB seeds is a major task for us now.

Key words:

Retinoblastoma; Seeds; Chemoreduction; Periocular injection; Intra-arterial perfusion; Intravitreous injection; Chemotherapy

Contributor Information

Chen Danian
Department of Ophthalmology and Ophthalmic Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, M5G1X5, Ontario, Canada
Gao Jingge
(Read 32 times, 1 visits today)
Updated: February 28, 2023 — 9:33 am